Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs

D. S. Streetman, A. N. Nafziger, Christopher J. Destache, Jr Bertino J.S.

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Study Objective. To examine the impact of individualized pharmacokinetic monitoring (IPM) on the development of aminoglycoside-associated nephrotoxicity (AAN). Design. Retrospective case-control study. Setting. Two teaching hospitals. Subjects. Two thousand four hundred five patients who received aminoglycosides. Intervention. Aminoglycoside therapy dosed by either IPM or physicians' directions. Measurements and Main Results. Patients receiving IPM were significantly less likely to develop AAN by both univariate (7.9% vs 13.2%, p=0.02) and multivariate methods (odds ratio 0.42, p=0.002). Female sex was protective against AAN. Age 50 years and above, high initial aminoglycoside trough, long duration of therapy, and concurrent piperacillin, clindamycin, or vancomycin increased risk of AAN. We estimated that IPM decreased AAN costs by $90,995/100 patients. Conclusion. Individualized pharmacokinetic monitoring significantly decreased the frequency of AAN and its associated economic costs.

Original languageEnglish
Pages (from-to)443-451
Number of pages9
JournalPharmacotherapy
Volume21
Issue number4
StatePublished - 2001
Externally publishedYes

Fingerprint

Aminoglycosides
Pharmacokinetics
Costs and Cost Analysis
Piperacillin
Clindamycin
Vancomycin
Teaching Hospitals
Case-Control Studies
Odds Ratio
Economics
Physicians
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. / Streetman, D. S.; Nafziger, A. N.; Destache, Christopher J.; Bertino J.S., Jr.

In: Pharmacotherapy, Vol. 21, No. 4, 2001, p. 443-451.

Research output: Contribution to journalArticle

@article{50d5ca88fd03491cbff27a7a6df2e9ba,
title = "Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs",
abstract = "Study Objective. To examine the impact of individualized pharmacokinetic monitoring (IPM) on the development of aminoglycoside-associated nephrotoxicity (AAN). Design. Retrospective case-control study. Setting. Two teaching hospitals. Subjects. Two thousand four hundred five patients who received aminoglycosides. Intervention. Aminoglycoside therapy dosed by either IPM or physicians' directions. Measurements and Main Results. Patients receiving IPM were significantly less likely to develop AAN by both univariate (7.9{\%} vs 13.2{\%}, p=0.02) and multivariate methods (odds ratio 0.42, p=0.002). Female sex was protective against AAN. Age 50 years and above, high initial aminoglycoside trough, long duration of therapy, and concurrent piperacillin, clindamycin, or vancomycin increased risk of AAN. We estimated that IPM decreased AAN costs by $90,995/100 patients. Conclusion. Individualized pharmacokinetic monitoring significantly decreased the frequency of AAN and its associated economic costs.",
author = "Streetman, {D. S.} and Nafziger, {A. N.} and Destache, {Christopher J.} and {Bertino J.S.}, Jr",
year = "2001",
language = "English",
volume = "21",
pages = "443--451",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs

AU - Streetman, D. S.

AU - Nafziger, A. N.

AU - Destache, Christopher J.

AU - Bertino J.S., Jr

PY - 2001

Y1 - 2001

N2 - Study Objective. To examine the impact of individualized pharmacokinetic monitoring (IPM) on the development of aminoglycoside-associated nephrotoxicity (AAN). Design. Retrospective case-control study. Setting. Two teaching hospitals. Subjects. Two thousand four hundred five patients who received aminoglycosides. Intervention. Aminoglycoside therapy dosed by either IPM or physicians' directions. Measurements and Main Results. Patients receiving IPM were significantly less likely to develop AAN by both univariate (7.9% vs 13.2%, p=0.02) and multivariate methods (odds ratio 0.42, p=0.002). Female sex was protective against AAN. Age 50 years and above, high initial aminoglycoside trough, long duration of therapy, and concurrent piperacillin, clindamycin, or vancomycin increased risk of AAN. We estimated that IPM decreased AAN costs by $90,995/100 patients. Conclusion. Individualized pharmacokinetic monitoring significantly decreased the frequency of AAN and its associated economic costs.

AB - Study Objective. To examine the impact of individualized pharmacokinetic monitoring (IPM) on the development of aminoglycoside-associated nephrotoxicity (AAN). Design. Retrospective case-control study. Setting. Two teaching hospitals. Subjects. Two thousand four hundred five patients who received aminoglycosides. Intervention. Aminoglycoside therapy dosed by either IPM or physicians' directions. Measurements and Main Results. Patients receiving IPM were significantly less likely to develop AAN by both univariate (7.9% vs 13.2%, p=0.02) and multivariate methods (odds ratio 0.42, p=0.002). Female sex was protective against AAN. Age 50 years and above, high initial aminoglycoside trough, long duration of therapy, and concurrent piperacillin, clindamycin, or vancomycin increased risk of AAN. We estimated that IPM decreased AAN costs by $90,995/100 patients. Conclusion. Individualized pharmacokinetic monitoring significantly decreased the frequency of AAN and its associated economic costs.

UR - http://www.scopus.com/inward/record.url?scp=0035066593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035066593&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 443

EP - 451

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 4

ER -